Bengt Rasmussen

Articles in journals

• Rasmussen, B. , Nilsson, L. , Tobiasson, M. , Jädersten, M. , Garelius, H. , Dybedal, I. , Grønbaek, K. , Ejerblad, E. & et al. (2025). Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide.  Genes, Chromosomes and Cancer, 64 (2). [BibTeX]
• Tobiasson, M. , Pandzic, T. , Illman, J. , Nilsson, L. , Weström, S. , Ejerblad, E. , Olesen, G. , Björklund, A. & et al. (2024). Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.  Journal of Clinical Oncology, 42 (12), 1378-1390. [BibTeX]
• Larfors, G. , Moreno Berggren, D. , Garelius, H. , Nilsson, L. , Rasmussen, B. , Hellström-Lindberg, E. & Ejerblad, E. (2023). MDS-Comorbidity Index using register data has prognostic impact in Swedish MDS patients.  Leukemia Research, 134. [BibTeX]
• Moreno Berggren, D. , Garelius, H. , Willner Hjelm, P. , Nilsson, L. , Rasmussen, B. , Weibull, C. E. , Lambe, M. , Lehmann, S. & et al. (2023). Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective.  Leukemia, 37 (5), 1103-1112. [BibTeX]
• Rasmussen, B. , Göhring, G. , Bernard, E. , Nilsson, L. , Tobiasson, M. , Jädersten, M. , Garelius, H. , Dybedal, I. & et al. (2022). "Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".  Leukemia, 36 (5), 1436-1439. [BibTeX]
• Larfors, G. , Moreno Berggren, D. , Garelius, H. , Jädersten, M. , Nilsson, L. , Rasmussen, B. & Ejerblad, E. (2021). Income, education and their impact on treatments and survival in patients with myelodysplastic syndromes.  European Journal of Haematology, 107 (2), 219-228. [BibTeX]
• Berggren, D. M. , Kjellander, M. , Backlund, E. , Engvall, M. , Garelius, H. , Lorenz, F. , Nilsson, L. , Rasmussen, B. & et al. (2021). Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study.  British Journal of Haematology, 192 (3), 474-483. [BibTeX]
• Berggren, D. M. , Folkvaljon, Y. , Engvall, M. , Sundberg, J. , Lambe, M. , Antunovic, P. , Garelius, H. , Lorenz, F. & et al. (2018). Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register.  British Journal of Haematology, 181 (5), 614-627. [BibTeX]

Conference papers

• Creignou, M. , Bernard, E. , Crowther, M. , Tranberg, A. , Ejerblad, E. , Nilsson, L. , Garelius, H. , Antunovic, P. & et al. (2022). Transfusion Patterns during Early Follow-up Predict Overall Survival Independently of IPSS-M in Patients with Myelodysplastic Syndromes. In:  Blood. Paper presented at 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA, USA, December 10-13, 2022,. (pp. 6968-6970). American Society of Hematology. [BibTeX]

Doctoral theses, comprehensive summaries

• Rasmussen, B. (2025). Clinical and genetic studies of high-risk myelodyplastic syndromes and acute myeloid leukemia with chromosome 5q deletion. (Doctoral dissertation). (Comprehensive summary) Örebro: Örebro University. [BibTeX]

Manuscripts

• Rasmussen, B. , Nilsson, L. , Tobiasson, M. , Jädersten, M. , Garelius, H. , Dybedal, I. , Grønbaek, K. , Ejerblad, E. & et al. Bone marrow trephine biopsy and immunohistochemistry are essential tools for diagnostic and therapeutic evaluation in higher-risk myelodysplastic syndrome and acute myeloid leukemia with del(5q). [BibTeX]